Yet, without exact knowledge of target cell–expressed CD19 levels, the extent to which CD19 εTRuC- or CD19 STAR-modified T cells achieve eradication of CD19low tumor cells, as they may emerge under selective pressure following CAR T cell therapy, remains to be identified. The gene discussed is CD19; the disease is neoplasm.